While our in vivo tumor growth data provide a strong rationale for pharmacological inhibition of Shp1 as a potential therapeutic approach for cancer, the development of a motheaten-like disease may represent a challenge with respect to tolerability. The gene discussed is PTPN6; the disease is cancer.